tert-butyl 4-[2-(trifluoromethyl)phenyl]-1,2,5,6-tetrahydropyridinecarboxylate | 308823-88-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl 4-[2-(trifluoromethyl)phenyl]-1,2,5,6-tetrahydropyridinecarboxylate
• 英文别名: tert-butyl 4-[2-(trifluoromethyl)phenyl]-3,6-dihydropyridine-1(2H)-carboxylate；tert-Butyl4-[2-(trifluoromethyl)phenyl]-3,6-dihydropyridine-1(2H)-carboxylate；tert-butyl 4-[2-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine-1-carboxylate
• CAS: 308823-88-3
• 化学式: C₁₇H₂₀F₃NO₂
• 分子量: 327.347
• InChiKey: FFVZUBIVLGQQDD-UHFFFAOYSA-N

物化性质

• 沸点：
  378.3±42.0 °C(Predicted)
• 密度：
  1.196±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-[2-(trifluoromethyl)phenyl]-1,2,5,6-tetrahydropyridinecarboxylate 在 palladium 10% on activated carbon 、 氢气 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 4-[2-(三氟甲基)苯基]哌啶
  参考文献：
  名称：

  设计，合成和评估基于取代哌啶的KCNQ开放剂作为新型抗癫痫药。

  摘要：

  癫痫病是一种发病机制复杂的疾病。KCNQ（Kv7）是电压依赖性钾离子通道，主要与癫痫有关，因此成为治疗癫痫的重要靶标。本文通过支架跳跃和活性亚结构杂交设计合成了一系列靶向KCNQ的取代哌啶衍生物。通过基于荧光的th流入测定，Rb +流动测定和电生理膜片钳测定来评估化合物。结果表明，某些化合物比瑞替加滨具有更强的钾通道开放活性。更重要的是，发现化合物11在体内具有良好的药代动力学特征。

  DOI：

  10.1016/j.bmcl.2018.04.040
• 作为产物：
  描述：

  1-Boc-4-(2-三氟甲基苯基)-4-哌啶醇 在 吡啶 、 氯化亚砜 作用下， 反应 17.0h， 生成 tert-butyl 4-[2-(trifluoromethyl)phenyl]-1,2,5,6-tetrahydropyridinecarboxylate
  参考文献：
  名称：

  3-Aminocyclopentanecarboxamides as modulators of chemokine receptors

  摘要：

  本发明涉及以下式的化合物： 这些化合物是趋化因子受体的调节剂。本发明的化合物及其组合物在治疗与趋化因子受体表达和/或活性相关的疾病方面是有用的。

  公开号：

  US20060004018A1

文献信息

• Substituted piperidines and methods of use
  申请人：——

  公开号：US20040006067A1

  公开（公告）日：2004-01-08

  Selected substituted piperidine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的替代哌啶化合物对预防和治疗疾病，如肥胖等，具有有效性。该发明涵盖了新颖化合物、类似物、前药和其药用可接受盐，以及用于预防和治疗涉及黑素皮质素受体激活的疾病和其他疾病或病症的药物组合物和方法。该发明还涉及制备此类化合物的方法，以及在此类方法中有用的中间体。
• Aromatic sulfone hydroxamic acids and their use as protease inhibitors
  申请人：——

  公开号：US20030073718A1

  公开（公告）日：2003-04-17

  This invention is directed to aromatic sulfone hydroxamates (also known as aromatic sulfone hydroxamic acids) and salts thereof that, inter alia, tend to inhibit matrix metalloproteinase (also known as matrix metalloprotease or MMP) activity and/or aggrecanase activity. This invention also is directed to a treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP activity and/or aggrecanase activity.

  本发明涉及芳香基磺酮羟肟酸（也称为芳香基磺酮羟肟酸）及其盐，该化合物在抑制基质金属蛋白酶（也称为基质金属蛋白酶或MMP）活性和/或聚集素酶（aggrecanase）活性方面具有倾向性。本发明还涉及一种治疗方法，其包括向动物，特别是患有（或有病理条件与MMP活性和/或聚集素酶活性相关的）哺乳动物中，以MMP抑制剂和/或聚集素酶抑制剂有效量的该化合物或盐进行治疗。
• 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
  申请人：Xue Chu-Biao

  公开号：US20060020133A1

  公开（公告）日：2006-01-26

  The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.

  本发明涉及化合物I的调节剂，化合物I的化学式为：该发明的化合物及其组合物在治疗与趋化因子受体表达和/或活性相关的疾病方面具有用途。
• 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS
  申请人：Xue Chu-Biao

  公开号：US20100119503A1

  公开（公告）日：2010-05-13

  The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.

  本发明涉及式I的化合物：它们是趋化因子受体的调节剂。本发明的化合物及其组合物在治疗与趋化因子受体表达和/或活性有关的疾病方面是有用的。
• Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARα/γ dual agonists
  作者：Eunkyung Kim、Chan Sun Park、Taedong Han、Myung-Ho Bae、Wonee Chong、Choong Hyun Lee、Young Ah Shin、Byung-Nak Ahn、Mi Kyung Kim、Chang Yell Shin、Moon Ho Son、Jin Kwan Kim、Ho Sang Moon、Hyun Joo Shim、Eun Jung Kim、Soon Hoe Kim、Joong In Lim、Chun Ho Lee

  DOI：10.1016/j.bmcl.2008.08.020

  日期：2008.9

  Aryl-tetrahydropyridine derivatives were prepared and their PPAR alpha/gamma dual agonistic activities were evaluated. Among them, compound (S)-5b was identified as a potent PPAR alpha/gamma dual agonist with an EC50 of 1.73 and 0.64 mu M in hPPAR alpha and gamma, respectively. In diabetic (db/db) mice, compound (S)-5b showed good glucose lowering efficacy and favorable pharmacokinetic properties. (C) 2008 Elsevier Ltd. All rights reserved.